NCT01208090

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 326 (actual)
• Sponsor: Actelion · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	ACT-128800	ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
DRUG	Placebo	ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

Timeline

• Start date: 2010-10-31
• Primary completion: 2012-10-31
• Completion: 2012-11-30
• First posted: 2010-09-23
• Last updated: 2025-03-30

Locations

67 sites across 17 countries: Austria, Belgium, Bulgaria, Czechia, Denmark, France, Hungary, Italy, Lithuania, Romania, Russia, Slovakia, Spain, Sweden, Switzerland, Ukraine, United Kingdom